Ischaemic conditioning is the phenomenon of protection against reperfusion injury via the application of brief, repeated episodes of non-lethal ischaemia. This review has three aims: 1) to briefly explain the various categories of ischaemic conditioning; 2) to explore past clinical trials and their failures; 3) to explore the future of clinical trials in the realm of ischaemic conditioning.
Introduction
Protecting the myocardium against lethal ischaemia necessitates rapid reperfusion. Paradoxically however, reperfusion injures the myocardium, a phenomenon known as "ischaemia-reperfusion injury" (IRI). There is currently no effective clinical intervention for IRI in spite of the fact that it may contribute up to 50% of final myocardial infarct (MI) size 1 . This review intends to describe past, present, and future clinical trials into ischaemic conditioning, which present one of the few avenues currently being explored clinically to kerb IRI.
The Principles of Ischaemic Conditioning and the Supporting Proof-of-Concept Studies
Ischaemic Conditioning is a form of protection against IRI produced via brief cycles of non-lethal ischaemia. These cycles may be sub-classified thusly (see also figure 1 o Remote Ischaemic Pre-conditioning (RIPC): brief cycles of non-lethal ischaemia induced at a "remote" limb via blood pressure cuff prior to an episode of lethal 3 myocardial ischaemia. The need to apply the conditioning prior to an ischaemic stimulus largely limits its application to the surgical arena where the time of onset of the injurious ischaemia can be readily predicted. Proof-of-concept studies have shown that RIPC has the capacity to reduce post-CABG troponin release in humans. 4, 5 Such an intervention is an attractive prospect due to its non-invasive nature. However, the recent outcome trials, RIPHEART and ERICCA, have been neutral and will be explored later in this review.
 Per-Conditioning
o Pharmacological Per-conditioning (PPerC): the use of pharmaceutical agents to mimic a conditioning stimulus during an ischaemic insult to protect against subsequent reperfusion injury. Proof-of-concept studies have shown cyclosporine-A (CsA) 6 and metoprolol 7 to be associated with a significant reduction in infarct size (measured by late-gadolinium enhancement on cardiac MRI). However, the large- Once again, no significant difference was seen between the primary end-points of either cohort.
Why was it that both of these trials failed to provide positive results? It may be that the injury suffered during CABG surgery is too small for RIPC to provoke a significant protective effect:
it is well recognised from the pre-clinical literature that the smaller the primary injury, the smaller the benefit from a conditioning intervention is likely to be. It is also important to consider the other therapies patients undergoing surgical procedures will be exposed to: all patients in RIPHeart and >90% of patients in ERICCA were anaesthetised with propofol, an 6 agent which might in-fact abolish RIPC-based cardio-protection and an important potential confounder 17 .
 PPerC -The 2015 CIRCUS ("Cyclosporine to ImpRove Clinical oUtcome in ST-elevation
Myocardial Infarction Patients") study 18 by Cung et al was a 970 patient, multicentre, doubleblinded RCT exploring CsA as a preconditioning agent in patients undergoing PPCI to treat STEMI. The primary end point was a 1-and 3-year composite of heart failure progression, rehospitalisation for heart failure, adverse left ventricular modelling, and all-cause death.
Prior to PPCI, patients were randomised to a CsA or placebo infusion. No significant difference in the primary end point was seen at 1 year: a neutral outcome. This could be due to the absence of data for LV end-diastolic volume in 17% of patients. This absent data, combined with the high incidence of adverse modelling in both cohorts, could have made it difficult to detect a significant difference in the other components of the primary end point composite.
The 2016 CYCLE ("CYCLosporinE A in Reperfused Acute Myocardial Infarction") study 19 by duration is either very short or very long 20 and it would seem that in clinical trials, the therapeutic window is typically in the order of 1-4 hours from symptom onset to revascularisation. Whether or not ischaemic time played a role in the neutral DANAMI 3-iPost study will require further analysis upon official publication.
The Future of Clinical Trials in Ischaemic Conditioning
A number of large outcome trials exploring ischaemic conditioning are currently underway and may yet still provide evidence for the introduction of conditioning techniques into clinical practice.
RIPerC in Primary PCI
The are a pair of collaborative studies investigating the use of RIPerC in STEMI patients. 21 The studies are both multicentre, multinational, double-blinded RCTs with 2300 patients and 2000 patients respectively. Both trials share identical primary endpoints of hospitalisation for heart failure or cardiovascular mortality at 1 year. In these trials, STEMI patients will be randomised to PPCI with or without RIPerC. The RIPerC will be delivered either in-ambulance or on arrival to the PPCI centre depending on average national transit time. The results of these trials are hoped to be released in approximately 18 months.
RIPerC in Thrombolysis
Though the ERIC-lysis 8 study provided evidence for clinically applied RIPerC, no large-scale trials have explored RIPerC in STEMI patients treated with thrombolysis. Whilst thrombolysis as an intervention 8 has largely been superseded by pPCI in the developed world, in the developing world thrombolysis is remains an important first-line therapy for STEMI. Large-scale human trials are still needed to provide evidence for a cost-neutral, life-saving therapeutic adjunct to thrombolysis.
PPerC in pPCI
Though the aforementioned CIRCUS 18 study of PPerC was neutral at 1 year, the trial has not yet completed follow-up. It may yet show an effect of CsA at the 3-year end-point and as such, full conclusions may not currently be drawn. It is also worth noting that CsA is not the sole pharmacological agent: there are multiple potential pharmacological targets within the increasingly well characterised cell-death pathway that may yet yield an efficacious PPerC option. Indeed, repurposing existing cardiovascular drugs may yield significant benefit to improve cardiovascular outcomes following an acute myocardial infarction.
Conclusion
Reperfusion injury plays a significant role in the evolution of the final myocardial infarct size yet physicians have no effective tools with which to combat the phenomenon. Recent small-scale human trials exploring the variety of ischaemic-conditioning modalities have shown some promise. If largescale trials can provide the evidence, reperfusion injury may yet become amenable to treatment. In remote conditioning exists a potentially cheap and non-invasive method of therapy, but as with pharmacological conditioning, the holy grail of an effective clinical intervention against IRI has yet to be realised. However, the search for an effective adjunct to reperfusion, if successful, will be wellrewarded by further reductions in cardiovascular mortality and morbidity and the consequent reduction upon the burgeoning socioeconomic healthcare burden worldwide. Cartoon summarising the various forms of conditioning -ischaemic, remote and pharmacological -and the terminology relative to the onset of injurious ischaemia and subsequent reperfusion. Modalities applied prior to injurious ischaemia are termed "preconditioning". A modality applied during the ischaemic injury is "perconditioning".
Figure legends
Any modality applied following the restoration of blood flow and reperfusion is regarded as "postconditioning".
